TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03726801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HEALTH EDUCATION
Description: The nursing intervention prior to surgery: (breast and colon cancer):~1. First phase: At first these subjects suffered a great emotional impact after knowing the diagnosis, which could generate intense anxiety reactions.~2. Second phase or phase of coping, in which they begin to be aware of their illness and the future changes they will suffer in their body. In this phase they react with fear, anger, anger, denial, ...~3. Third phase or phase of adaptation to the new situation, where there is a decrease in previous emotional reactions, the patient being able to start up the resources learned to reduce their psychological discomfort.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: HEALTH EDUCATION
Description: The nursing intervention prior to surgery: (breast and colon cancer):~1. First phase: At first these subjects suffered a great emotional impact after knowing the diagnosis, which could generate intense anxiety reactions.~2. Second phase or phase of coping, in which they begin to be aware of their illness and the future changes they will suffer in their body. In this phase they react with fear, anger, anger, denial, ...~3. Third phase or phase of adaptation to the new situation, where there is a decrease in previous emotional reactions, the patient being able to start up the resources learned to reduce their psychological discomfort.
Study: NCT03166839

Intervention type: OTHER
Intervention: Experiencing PPH
Description: No intervention given

Intervention type: OTHER
Intervention: Experiencing PPH
Description: No intervention given

Intervention type: OTHER
Intervention: Experiencing PPH
Description: No intervention given
Study: NCT01890759

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Diphtheria Toxoid Vaccine
Description: 0.5 mL, Intramuscular
Study: NCT03372382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: NSAID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: NSAID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: analgesic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norco
Description: acetaminophen plus opioid
Study: NCT04253379

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological evaluation , Evaluation of theory of mind, Evaluation of executive functions, Evaluation of verbal skills
Description: Several tests will be used: Raven's Advanced Progressive Matrices, auditory attention subtest of the NEPSY II, Peabody Picture Vocabulary test, specific comprehension test The cognitive TOM will be evaluated with questions about 4 stories of false beliefs. The affective TOM will be evaluated with a specific emotion inference task 4 adapted subtests from several validated scales will be used to investigate inhibition, cognitive flexibility and working memory The semantic and pragmatic competences will be evaluated with 4 comprehension tasks.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation , Evaluation of theory of mind, Evaluation of executive functions, Evaluation of verbal skills
Description: Several tests will be used: Raven's Advanced Progressive Matrices, auditory attention subtest of the NEPSY II, Peabody Picture Vocabulary test, specific comprehension test The cognitive TOM will be evaluated with questions about 4 stories of false beliefs. The affective TOM will be evaluated with a specific emotion inference task 4 adapted subtests from several validated scales will be used to investigate inhibition, cognitive flexibility and working memory The semantic and pragmatic competences will be evaluated with 4 comprehension tasks.
Study: NCT00920504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: German PRO-SELF(c) Plus Pain Control Program (PCP)
Description: Educational intervention directed at patients and their family caregivers to reduce cancer pain and related symptoms

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: German PRO-SELF(c) Plus Pain Control Program (PCP)
Description: Educational intervention directed at patients and their family caregivers to reduce cancer pain and related symptoms

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Patients in the standard care group will receive routine care provided by their treating physicians without any further care concerning the PRO-SELF© PCP. Patients in the standard care group will be seen by a research nurse in their homes at weeks 1, 2, 4, 6, 8 and 10 and telephone interviews will be conducted at weeks 3, 5, 7 and 9 but the focus of the visits and phone calls will be data collection only.
Study: NCT02153125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Study: NCT03052920

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear implant
Description: Participants who have failed a BiCROS or bilateral hearing aid trial and otherwise meet inclusion criteria will receive a cochlear implant at the poor hearing ear. Post-implant, participants will continue use of a hearing aid at the better ear and the cochlear implant at the poor ear.
Study: NCT03584230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned to positive group
Description: See arm description

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assigned to negative group
Description: See arm description
Study: NCT03075332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined training
Description: Combined training consisting of aerobic and resisted training in the same training session for 15 weeks followed by 5 weeks of detraining
Study: NCT00823602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ganirelix
Description: These patients started ovarian stimulation with 150 - 225 IU Gonal F on the second day of menstrual cycle with an S.C. injection once a day. Initiation of 0.25 mg Ganirelix took place on the 6th of the stimulation (fixed protocol) when HMG (Menogon, ferring, pharmacenticals , Germany ).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: suprefact
Description: GnRH agonist, standard protocol
Study: NCT04177992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Servo control
Description: FiO2 adjustments will be made by one of two respiratory devices depending on the clinical requirements and current ventilatory therapy of the infant
Study: NCT03536663

Intervention type: DEVICE
Group type: OTHER
Intervention: Optiflux and Dialyzer with Endexo
Description: Hemodialysis (HD) on Optiflux dialyzer from Visit 1 to 12 and followed by HD on the dialyzer with Endexo at visit 13 and continues until visit 50. Dialysis is performed 3 times per week which means the total of the intervention will be 17 weeks.
Study: NCT01542086

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myocardial SPECT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 64-channel coronary CT angiography (CCTA)
Study: NCT02423811

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fursultiamine
Description: Use of Fursultiamine in addition to CCRT
Study: NCT02442206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVA149
Description: QVA149 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to QVA140 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to QVA140 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily
Study: NCT02849886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T lymphocytes iCASP9 ΔCD19
Description: Intravenous injection of the T lymphocytes armed with the iCASP9 suicide gene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T lymphocytes iCASP9 ΔCD19
Description: Intravenous injection of the T lymphocytes armed with the iCASP9 suicide gene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimerizer drug AP1903
Description: AP1903 drug will be administrated at a dose of 0.4 mg/kg by intravenous route in the two following cases:~* Acute Grade ≥II or symptomatic Grade I GvHD justifying systemic immunosuppression therapy;~* Grade ≥3 toxicity attributable to GMC.
Study: NCT02594059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: endothelial function
Description: measure of reactive hyperemia-peripheral artery tone index
Study: NCT04508647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Ublituximab will be administered as an intravenous infusion through a dedicated line. All infusions will be administered per institutional guidelines.~During ublituximab monotherapy (initial treatment), Cycle 1 Day 1 administration time frame: Over 4 hours. Cycle 1 days 8 and 15 will be over 3 hours, and Cycle 1 Day 22 will be over 90 minutes. During combination treatment with umbralisib, ublituximab will be administered over 90 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Ublituximab will be administered as an intravenous infusion through a dedicated line. All infusions will be administered per institutional guidelines.~During ublituximab monotherapy (initial treatment), Cycle 1 Day 1 administration time frame: Over 4 hours. Cycle 1 days 8 and 15 will be over 3 hours, and Cycle 1 Day 22 will be over 90 minutes. During combination treatment with umbralisib, ublituximab will be administered over 90 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: Umbralisib will be administered orally once daily within 30 minutes of starting a meal.
Study: NCT02830399

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active rTMS-ECT
Description: 5 High Frequency (20Hz) rTMS (applicated on the left prefrontal dorsolateral cortex) before 5 bilateral ECT

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham rTMS-ECT
Description: 5 sham rTMS (applicated on the left prefrontal dorsolateral cortex) before 5 bilateral ECT
Study: NCT02425735

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK cells
Description: DC-CIK cells will be used against tumor cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: γδ T cells
Description: γδ T cells will be used against breast tumor.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: γδ T/DC-CIK cells
Description: γδ T/DC-CIK cells will be used against breast tumor.
Study: NCT03915626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine (RLD) transdermal patch
Description: brand name patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine (RLD) transdermal patch
Description: brand name patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine (generic) transdermal patch
Description: generic patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine (generic) transdermal patch
Description: generic patch
Study: NCT03166488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Subjects will receive an MRI sequence called Magnetic Resonance Elastography (MRE).
Study: NCT03287115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Broccoli consumption
Description: All subjects will eat broccoli on day 11
Study: NCT04117542

Intervention type: OTHER
Intervention: Observational
Description: Observational data will be obtained through participant self-response, parental response, cognitive performance, and neural imaging.

Intervention type: OTHER
Intervention: Observational
Description: Observational data will be obtained through participant self-response, parental response, cognitive performance, and neural imaging.
Study: NCT01901016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jacobson progressive muscular relaxation
Description: PMR involves learning to identify the tension in specific muscle groups by tightening and relaxing each muscle group. It includes three different exercises: 1) contraction-relaxation of 12 large muscle groups in the arms, legs, and trunk; 2) identification and relaxation of tensions without the need for movement or contractions; and 3) contraction-relaxation of 12 small muscle groups in the neck, eyes, and mouth

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Schultz's autogenic training
Description: AT is a relaxation technique that is based on body attitude, reduction of exterior stimulation, inner concentration, and mental repetition of verbal formulas \[28\]. These formulas are organized into six exercises: 1) heaviness; 2) warmth; 3) calm and regular heart function; 4) self-regulation of respiration; 5) warmth in the upper abdominal area; and 6) agreeable cooling of the forehead.
Study: NCT00869310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aprepitant + dexamethasone
Description: Dexamethasone 8 mg orally: 24 hours after chemotherapy (day 2) and then at 8 am on days 3-4 plus Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide + dexamethasone
Description: dexamethasone 8 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am and 8 pm on days 3-4 plus Metoclopramide 20 mg orally 4 times a day: 24 hours after chemotherapy and then at 4 pm, 7 pm, 10 pm on day 2 then at 7 am, 12 am, 5 pm, 10 pm on days 3-4.
Study: NCT03190785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Benzoic acid washout and exposure
Description: see above
Study: NCT01277432

Intervention type: OTHER
Intervention: Psychiatrist Interview
Description: Patients will receive a face-to-face interview by a trained clinician or psychiatrist using the following instruments:~* MINI~* SSI-28 (somatization)

Intervention type: OTHER
Intervention: Depression screening - control
Description: All study participants will undergo;~1. a comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal~2. a detailed psychological and behavioral assessments using validated questionnaires~3. several specialist questionnaires on depression, self care and quality of life
Study: NCT02113007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab plus Temozolomide
Description: Treatment cycles will be repeated every 14 days (2 weeks) for the lead-in portion. If no prohibitive toxicities are observed in the first 6 patients during the first 2 treatment cycles, the study will continue enrolling patients. Treatment cycles for the Phase II portion will be repeated every 14 days (2 weeks) for a total of 12 cycles.
Study: NCT03883776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Al18F-NOTA-octreotide
Description: One intravenous injection of 4 MBq/kg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Part 1: Healthy volunteers will undergo consecutive whole-body PET scans, including one low-dose CT, for the first 90 minutes. At 150 ± 15 min and 300 ± 30 min post injection two additional static whole-body PET/CT scans will be acquired.~Part 2: Neuroendocrine tumor patients will undergo a dynamic PET scan for the first 45 minutes, followed by 3 static whole-body PET/CTs at 60 ± 10 min, 120 ± 30 min and 180 ± 30 min post injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Venous blood samples
Description: Blood samples will be obtained for laboratory safety evaluation for initial screening and safety evaluation after injection. Furthermore, venous blood samples will be obtained for metabolite analysis and activity measurements (only for patients) at various time points post injection (5 ± 2 min, 10 ± 5 min, 20 ± 10 min, 40 ± 20 min, 60 ± 30 min, 120 ± 60 min).
Study: NCT02686814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 17mm MDT-2215 aortic valve bioprosthesis
Study: NCT02311933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endoxifen Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Citrate
Description: Given PO
Study: NCT01767311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab 2.5 mg/kg
Description: 2.5 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab 5.0 mg/kg
Description: 5.0 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab 10 mg/kg
Description: 10 mg/kg biweekly (once every 2 weeks) administered as i.v. infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab 5.0 mg/kg
Description: 5.0 mg/kg monthly (once every 4 weeks) administered as i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab 10 mg/kg
Description: 10 mg/kg monthly (once every 4 weeks) administered as i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: biweekly (once every 2 weeks) administered as i.v. infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab 10 mg/kg
Description: 10 mg/kg biweekly (once every 2 weeks), once every 4 weeks (Q4W) or once every 3 months (Q3M) i.v. infusion.
Study: NCT03965923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine (DPV) Vaginal Ring (VR)
Description: Vaginal ring containing 25 mg of DPV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine (DPV) Vaginal Ring (VR)
Description: Vaginal ring containing 25 mg of DPV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine (DPV) Vaginal Ring (VR)
Description: Vaginal ring containing 25 mg of DPV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada Tablet
Description: Tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada Tablet
Description: Tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada Tablet
Description: Tablet taken orally
Study: NCT02531126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPC1063
Study: NCT04729686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular Nerve Block
Description: Per Standard Institutional Practice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fascia Iliaca Nerve Block
Description: Per Standard Institutional Practice
Study: NCT04071236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peposertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peposertib
Description: Given PO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radium Ra 223 Dichloride
Description: Given IV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radium Ra 223 Dichloride
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radium Ra 223 Dichloride
Description: Given IV
Study: NCT03547258

Intervention type: GENETIC
Intervention: Clinical and Molecular data collection
Description: Clinical and Molecular data collection at diagnosis, during treatment and at each relapse
Study: NCT00082186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosentan
Description: Oral bosentan tablets 62.5 mg twice daly for 4 weeks, then 125 mg twice daily for 20 weeks.
Study: NCT04416919

Intervention type: OTHER
Group type: OTHER
Intervention: Assembled mask
Description: Assembled masks consisting of 3 parts: A facemask (Respironics Performax Whole Face Mask or Hans Rudolph mask naso-oral mask) linked by a blue elbow ( RP Performax SE ELBOW) to a ventilator filter (Teleflex Bacterial/Viral filter 1605 or Iso-Gard HEPA light Filter 28022)
Study: NCT02328482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tehalose 30gr
Description: Trehalose 30 g for IV infusion administered every week over an additional 52 weeks
Study: NCT01677182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon tablets for sublingual administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon
Description: Ramelteon tablets for sublingual administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching tablets for sublingual administration
Study: NCT02706769

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study medication contains blinded placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Study medication contains blinded paracetamol